2022年美国癌症研究协会（AACR）年会即将于4月8-13日在美国New Orleans召开。云顶国际将在会议上公布多项自主研发全人单抗、双抗、双抗ADC新药的研究成果，以及创新动物模型在药物评价中的应用研究，并在会议现场设立展台#1043。

一、多项新药研究及技术平台成果：

1.TNFR2非阻断型全人抗体药物（1C3）

标题：1C3, a Novel Non-blocking Anti-human TNFR2 Antibody Generated From RenMice, Exhibits Promising Anti-tumor Activity and Safety in Syngeneic Tumor Models in Humanized TNFR2 Mice

话题：Immunology

编号：2907

展示时间：Tuesday, April 12th 9:00 AM-12:30 PM Poster Session

简介：1C3是一款新型TNFR2非阻断治疗抗体，能够促进CD8+ T细胞增殖，增加肿瘤微环境中效应T细胞的比例。该药物由云顶国际与宝船生物合作开发，经云顶国际自主研发RenMice小鼠进行抗体发现，B-hTNFR2小鼠体内高通量筛选获得。临床前研究表明1C3单药及与PD-1或PD-L1抗体联用在小鼠肿瘤模型中均有良好的抗肿瘤活性。

2.Her2-Trop2全人双抗ADC（YH012）

标题：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

话题：Immunology

编号：4256

展示时间：Wednesday, April 13th 9:00 AM-12:30 PM Poster Session

简介：YH012是一款云顶国际自主研发的HER2-TROP2全人双特异性抗体偶联药物（双抗ADC）。HER2与TROP2在胃癌、结直肠癌、膀胱癌和乳腺癌等多种肿瘤上共表达。临床前研究中，HER2-TROP2 BsAb与母本单抗相比增加了内吞活性，而单价HER2或TROP2单抗内吞活性降低，YH012较单抗HER2/TROP2-ADC具有更强的体外细胞杀伤活性。YH012在非小细胞肺癌和胃癌CDX小鼠模型体内均显示出良好的抗肿瘤活性。

3.PD-1-CD40 双特异性抗体（YH008）

标题：YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling

话题： Immunology

编号： 5615

展示形式：E-Poster

简介：YH008是一款抗PD-1/CD40 Fc沉默的IgG1亚型双特异性抗体。临床前研究中，YH008在B-hPD-1/CD40小鼠B16F10肿瘤模型中显示出剂量依赖的抗肿瘤活性，该抗体以PD-1依赖的方式激活CD40，促进树突细胞增殖和活化，增加肿瘤浸润CD8+ T细胞/Treg细胞比率。在100 mg/kg的高剂量下，YH008未升高B-hPD1/hCD40小鼠血液中的肝酶。同样，在食蟹猴剂量递增研究中未观察到显著不良事件。YH008目前处于临床前开发阶段，预计于2022年递交IND申请。

4. 新型TCRm抗体药物开发平台

标题：Generation of TCR-like fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice

话题：Therapeutic antibodies

编号：2885

简介：云顶国际建立了基于HLA/RenMice小鼠的TCRm抗体开发平台，能够很好的针对胞内抗原靶点进行高通量的TCRm抗体开发，较天然TCR相比，TCRm抗体具有更高的亲和力和特异性。

5.规模化抗体新药开发-“千鼠万抗”计划（RenMice HiTS Platform）

标题：Identifying New Therapeutic Antibodies Using Knockout Mice Expressing Human Immunoglobulin Variable Domain Genes

话题：Experimental and Molecular Therapeutics

编号： 1891

二、BioMice人源化动物模型在新药临床前评价应用研究：

Sunday, April 10th 1:30-5:00 PM Poster Session

1.B-hGLPR Mice

#3:Developing a Translational Tool for GLP-1-Based Therapeutic Agonists in Humanized GLP1R Mice

2.B-hTFR1 Mice

#377:Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

Monday, April 11th 1:30-5:00 PM Poster Session

3. B-hIL21R Mice and B-hPD-1/hIL21R Mice

#1641:Evaluating In Vivo Efficacy of Bi-Functional Fusion Protein Anti-PD-1-IL21 in Humanized B-hIL21R Mice and B-hPD-1/hIL21R Mice

4. B-hVSIG4 Mice

#1642:Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice

5. B-hIL12A/hIL12B/hIL12RB1/hIL12RB2 Mice

#1643:B-hIL12A/hIL12B/hIL12RB1/hIL12RB2: A Novel Animal Model for Generation of IL12 Therapies

6.B-hGARP Mice

#1644:Generation and Validation of Humanized GARP Mice for Testing Novel Anti-Human GARP Antibodies

7.B-hCD16A Mice

#1645:Advancing the Development of CD16A-Based Bispecific Antibodies in Humanized CD16A Mouse Models

8.B-hTROP2 Mice

#1646:Humanized TROP2 Mice Provide a Preclinical Tool for the Evaluation of Therapeutic Drugs Targeting TROP2

9. B-hCSF1/hCSF1R Mice

#1648:Evaluation of Therapeutic Drug Candidates Using a Novel Humanized B-hCSF1/hCSF1R

10. B-hPVRIG Mice

#1649:Humanized PVRIG Mice: A Novel Tool for Evaluating Anti-PVRIG Immunotherapies

11.B-hTLR8 Mice

#1651:Generation of a Novel Humanized TLR8 Mouse Model for the Evaluation of Human TLR8 Agonists and Antibody-Conjugated TLR8 Agonists

12.B-hB7-H4 Mice

#1652:A Humanized Mouse Model of the Promising Immune Checkpoint Molecule B7-H4

13. B-HLA-A2.1 Mice

#1992:Evaluating In Vivo Efficacy of Peptide Vaccines in Humanized B-HLA-A2.1 Mice

14. B-hTSLP/hTSLPR Mice

#2089:Functional Analysis of Anti-TSLP Antibodies Using Humanized B-hTSLP/hTSLPR Mice

15.B-hIL36R Mice

#2090:Humanized IL36R Mice Provide a Preclinical Tool for the Evaluation of Therapeutic Drugs Targeting IL36R